title: Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma.
abstract: Although prognosis in patients with localized osteosarcoma has been dramatically improved by the introduction of multiple chemotherapy agents known as combination chemotherapy, there is growing concern about the development of secondary malignant neoplasms. We report the case of a 13-year-old girl in whom the diagnosis of Ewing sarcoma of bone localized on the shaft of left femur was made 2 years after successful treatment without radiotherapy for osteosarcoma of right proximal femur. EWS-FLI1 fusion gene was detected by reverse transcriptase-polymerase chain reaction. To our knowledge, this is the first case with Ewing sarcoma of the bone as a secondary malignant neoplasm developed in osteosarcoma survivor. We collected 15 cases, included this case, with secondary Ewing sarcoma family of tumor by utilizing the PubMed search and might consider the causes of this secondary cancer.
authors.affiliation: Departments of *Pediatrics †Orthopaedic Surgery ‡Molecular and Laboratory Medicine, Mie University Graduate School of Medicine §Pathology Division, Mie University Hospital, Mie, Japan.
authors.forename: Noriko
authors.initials: N
authors.lastname: Yodoya
authors.forename: Shotaro
authors.initials: S
authors.lastname: Iwamoto
authors.forename: Akihiko
authors.initials: A
authors.lastname: Matsumine
authors.forename: Eiichi
authors.initials: E
authors.lastname: Azuma
authors.forename: Hidemi
authors.initials: H
authors.lastname: Toyoda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Miura
authors.forename: Kaname
authors.initials: K
authors.lastname: Nakatani
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hirayama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Komada
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005266:Femoral Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000601:surgery; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D023821:Limb Salvage; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery; D051789:Proto-Oncogene Protein c-fli-1 / Q000235:genetics*; D034802:RNA-Binding Protein EWS / Q000235:genetics*; D012074:Remission Induction; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage
chemical_list: C106031:EWS-FLI fusion protein; D015514:Oncogene Proteins, Fusion; D051789:Proto-Oncogene Protein c-fli-1; D034802:RNA-Binding Protein EWS; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; C027260:pirarubicin; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate